Background Immune checkpoint inhibitor (ICI) monoclonal antibodies (mAbs) targeting
cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or its …

The enthusiasm for immune checkpoint inhibitors (ICIs), an efficient tumor treatment model
different from traditional treatment, is based on their unprecedented antitumor effect, but the …

Background Immune-related adverse events (irAEs) are frequently reported during immune
checkpoint inhibitor (ICI) therapy and are associated with long-term outcomes. It is unknown …

Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for
patients with many advanced malignancies, only 15–60% of patients respond, leaving a …

Background Immune-related adverse events (irAE) induced by immune checkpoint inhibitors
(ICI) are a treatment-limiting barrier. There are few large-scale studies that estimate irAE …

Immune-related adverse events (irAE) have been described with immune checkpoint
inhibitors (ICI), but the incidence and relative risk (RR) of irAEs associated with these drugs …

Simple Summary This study examined the real-world experience and occurrence of immune-
related adverse events (irAEs) under cancer checkpoint immunotherapy, and the …

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving
outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and …

Background Targeting immune checkpoints is a novel approach in cancer therapy. This
strategy may trigger immune related adverse events (irAE). We hypothesize that the …

Background A number of studies have reported an association between the occurrence of
immune-related adverse events (irAEs) and clinical efficacy in patients undergoing treatment …